First-in-human transcatheter mitral valve replacement cases show safety, efficacy (Dr. Anson Cheung)
Transcatheter mitral valve replacement may soon be another tool in the interventional toolbox, as highlighted by a first-in-human series demonstrating safety and feasibility in two Canadian patients with severe mitral regurgitation (MR). The results are being published in the October 28, 2014, issue of the Journal of the American College of Cardiology.
“Catheter-based mitral valve implantation is technically feasible and may present another chapter in the evolution in the treatment of valvular heart disease,” Anson Cheung, MD, of St. Paul’s Hospital (Vancouver, Canada), and colleagues write.
For this case series, Dr. Cheung and colleagues implanted the device into two patients with end-stage ischemic cardiomyopathy and severe MR.
Yael L. Maxwell reports
Providence Health Care President and CEO Dianne Doyle